Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12–13 May 2017

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Therapeutic Advances in Vaccines

• Publication date

  2017-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1177/2051013617720659PMID 28794878PMCID PMC5524245
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model

  2017cited by this paper
• Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy.

  2017cited by this paper
• Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

  2017cited by this paper
• Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients

  2017cited by this paper
• Systematic evaluation of immune regulation and modulation

  2017cited by this paper
• Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)

  2017cited by this paper
• Immunotherapy for the treatment of Hodgkin lymphoma

  2017cited by this paper
• Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years’ Experience: A Meta-Analysis of 3312 Patients

  2017cited by this paper
• Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

  2016cited by this paper
• Lessons learned from cancer vaccine trials and target antigen choice

  2016cited by this paper
• Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed

  2016cited by this paper
• SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors

  2016cited by this paper
• In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

  2016cited by this paper
• Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators

  2016cited by this paper
• Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity.

  2016cited by this paper
• SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade

  2016cited by this paper
• Oncolytic virus therapy: A new era of cancer treatment at dawn

  2016cited by this paper
• Current understanding of interactions between nanoparticles and the immune system.

  2016cited by this paper
• Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression

  2016cited by this paper
• The molecular mechanism of thalidomide analogs in hematologic malignancies

  2016cited by this paper
• Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine

  2016cited by this paper
• Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

  2016cited by this paper
• Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells

  2016cited by this paper
• Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity

  2016cited by this paper
• Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome

  2016cited by this paper
• Autophagy, citrullination and cancer

  2016cited by this paper
• Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses

  2016cited by this paper
• High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.

  2016cited by this paper
• Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.

  2016cited by this paper
• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  2016cited by this paper
• Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy.

  2016cited by this paper
• PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

  2015cited by this paper
• Rapid eradication of a bulky melanoma mass with one dose of immunotherapy.

  2015cited by this paper
• Evolving synergistic combinations of targeted immunotherapies to combat cancer

  2015cited by this paper
• Elevated chronic inflammatory factors and myeloid‐derived suppressor cells indicate poor prognosis in advanced melanoma patients

  2015cited by this paper
• Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation

  2015cited by this paper
• Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory

  2015cited by this paper
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• MDSC and TGFβ Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes.

  2015cited by this paper
• Reduced expression of GDF‐15 is associated with atrophic inflammatory lesions of the prostate

  2015cited by this paper
• Rationale for combining immunotherapy with chemotherapy.

  2015cited by this paper
• A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma

  2014cited by this paper
• Characterization of the ripoptosome and its components: implications for anti-inflammatory and cancer therapy.

  2014cited by this paper
• A novel combinatorial cancer immunotherapy

  2014cited by this paper
• Nano-Gold Corking and Enzymatic Uncorking of Carbon Nanotube Cups

  2014cited by this paper
• The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors

  2014cited by this paper
• Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch

  2014cited by this paper
• Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

  2014cited by this paper
• Enhanced cross‐priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide

  2013cited by this paper
• Clinical evaluation of systemic and local immune responses in cancer: time for integration

  2013cited by this paper
• HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Diagnostic Accuracy of Maternal Serum Macrophage Inhibitory Cytokine-1 and Pregnancy-Associated Plasma Protein-A at 6–10 Weeks of Gestation to Predict Miscarriage

  2012cited by this paper
• Novel insights into the molecular mechanisms of HLA class I abnormalities

  2012cited by this paper
• Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients

  2012cited by this paper
• Therapeutic cancer vaccines: current status and moving forward.

  2012cited by this paper
• Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism

  2011cited by this paper
• Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model

  2011cited by this paper
• Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface

  2011cited by this paper
• Targeting the extrinsic apoptosis signaling pathway for cancer therapy

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Therapeutic cancer vaccines.

  2010cited by this paper
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

  2010cited by this paper
• Antibodies designed as effective cancer vaccines

  2009cited by this paper
• Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

  2009cited by this paper
• Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.

  2008cited by this paper

• Immune Targeting of Oncogenic HPV as Therapy for Cancer

  2020cites this paper
• Immunotherapies Targeting a Tumor-Associated Antigen 5T4 Oncofetal Glycoprotein

  2020cites this paper
• Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen

  2019cites this paper
• Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy.

  2016cites this paper